DE69532031D1 - Schilddrüsenhormone enthaltende mittel - Google Patents

Schilddrüsenhormone enthaltende mittel

Info

Publication number
DE69532031D1
DE69532031D1 DE69532031T DE69532031T DE69532031D1 DE 69532031 D1 DE69532031 D1 DE 69532031D1 DE 69532031 T DE69532031 T DE 69532031T DE 69532031 T DE69532031 T DE 69532031T DE 69532031 D1 DE69532031 D1 DE 69532031D1
Authority
DE
Germany
Prior art keywords
pct
mass
agent
sec
thyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69532031T
Other languages
English (en)
Other versions
DE69532031T2 (de
Inventor
Karrar Ahmad Khan
Alan Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of DE69532031D1 publication Critical patent/DE69532031D1/de
Publication of DE69532031T2 publication Critical patent/DE69532031T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
DE69532031T 1994-02-01 1995-01-30 Schilddrüsenhormone enthaltende mittel Expired - Fee Related DE69532031T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9401892A GB9401892D0 (en) 1994-02-01 1994-02-01 Therapeutic agents
GB9401892 1994-02-01
PCT/EP1995/000321 WO1995020953A1 (en) 1994-02-01 1995-01-30 Therapeutic agents containing thyroid hormones

Publications (2)

Publication Number Publication Date
DE69532031D1 true DE69532031D1 (de) 2003-12-04
DE69532031T2 DE69532031T2 (de) 2004-07-22

Family

ID=10749669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532031T Expired - Fee Related DE69532031T2 (de) 1994-02-01 1995-01-30 Schilddrüsenhormone enthaltende mittel

Country Status (11)

Country Link
US (1) US5753254A (de)
EP (1) EP0732920B1 (de)
AT (1) ATE252899T1 (de)
AU (1) AU1537095A (de)
CA (1) CA2182038A1 (de)
DE (1) DE69532031T2 (de)
ES (1) ES2210282T3 (de)
GB (1) GB9401892D0 (de)
IL (1) IL112518A0 (de)
WO (1) WO1995020953A1 (de)
ZA (1) ZA95741B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271863T1 (de) * 1995-11-14 2004-08-15 Abbott Gmbh & Co Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
DE69727922T2 (de) * 1996-04-16 2005-01-20 Novartis Consumer Health S.A. Schnell zerfallende orale dosierungsform
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
JP2001122785A (ja) * 1999-10-22 2001-05-08 Nippon Boehringer Ingelheim Co Ltd ブロチゾラムを含有する錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6620611B2 (en) * 2001-01-06 2003-09-16 Geovation Technologies, Inc. Solid-chemical composition for sustained release of organic substrates and complex inorganic phosphates for bioremediation
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
KR20040100835A (ko) * 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20020193440A1 (en) * 2001-02-20 2002-12-19 Ritter Steven C. Liothyronine sodium and levothyroxine sodium combination
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
WO2003013441A2 (en) * 2001-08-10 2003-02-20 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
AU2002341555A1 (en) * 2001-08-14 2003-09-02 King Pharmaceuticals, Inc. Levothyroxine pharmaceutical compositions, methods of making and methods of administration
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2003268078A1 (en) * 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
AU2003290613A1 (en) * 2002-11-05 2004-06-07 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
EP2428516A1 (de) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Neue Phosphor enthaltende Thyromimetika
EP1734931A2 (de) * 2004-03-24 2006-12-27 Actavis Group Formulierungen von ramipril
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JP2008545711A (ja) * 2005-05-26 2008-12-18 メタバシス・セラピューティクス・インコーポレイテッド 新規ホスフィン酸含有甲状腺ホルモン様剤
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
SI2694471T1 (sl) * 2011-04-08 2017-12-29 Bracco Imaging S.P.A. Postopek priprave sulfatiranega derivata 3,5-dijodo-O-(3-jodofenil)-L-tirozina
MY184400A (en) * 2012-08-20 2021-04-01 Merck Patent Gmbh Solid pharmaceutical preparation containing levothyroxine
EP2932963A1 (de) 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stabile pharmazeutische Darreichungsformen enthaltend Levothyroxine Natrium
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
CN106420625B (zh) * 2015-08-12 2021-02-26 北京科信必成医药科技发展有限公司 一种稳定的盐酸氨溴索掩味颗粒及其制备方法
CN106389339B (zh) * 2015-08-12 2020-08-04 北京科信必成医药科技发展有限公司 一种阿司匹林无水吞服掩味颗粒及其制备方法
KR102338803B1 (ko) * 2016-05-03 2021-12-14 스펙트릭스 테라퓨틱스, 엘엘씨 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
EP3452077A4 (de) * 2016-05-03 2020-01-08 Spectrix Therapeutics, LLC Zusammensetzungen und verfahren zur bereitstellung von schilddrüsenhormon oder analoga davon
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA680863A (en) * 1964-02-25 G. Ginger Leonard Compositions containing d-isomers of thyronine
US3157574A (en) * 1959-05-01 1964-11-17 Smith Kline French Lab Method of reducing cholesterol levels
US3090724A (en) * 1961-01-03 1963-05-21 Baxter Laboratories Inc Method of treating dermatological conditions
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69224809T2 (de) * 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe

Also Published As

Publication number Publication date
CA2182038A1 (en) 1995-08-10
ES2210282T3 (es) 2004-07-01
US5753254A (en) 1998-05-19
IL112518A0 (en) 1995-12-08
AU1537095A (en) 1995-08-21
DE69532031T2 (de) 2004-07-22
WO1995020953A1 (en) 1995-08-10
ATE252899T1 (de) 2003-11-15
GB9401892D0 (en) 1994-03-30
ZA95741B (en) 1995-08-01
EP0732920B1 (de) 2003-10-29
EP0732920A1 (de) 1996-09-25

Similar Documents

Publication Publication Date Title
DE69532031D1 (de) Schilddrüsenhormone enthaltende mittel
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
DK0893992T3 (da) Hurtigt sönderdelende oral doseringsform
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
GEP20022784B (en) Celecoxib Composition
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
MX9501848A (es) Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
ES8307496A1 (es) Procedimiento para la obtencion de una preparacion galenica antagonista al calcio.
FR2756561B1 (fr) Composes heteroaryles, compositions pharmaceutiques et cosmetiques les contenant et utilisations
FR2500303B1 (de)
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
GB9216859D0 (en) Medicaments
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
FR2718610B1 (fr) Nouvelles formulations pesticides et leur procédé de préparation.
TNSN94110A1 (fr) Procede de preparation de compositions orales contenant des quinolones
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
RU94025799A (ru) Способ лечения идиопатического дерматомиозита
MX9605916A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticos y cosmeticas que los contienen y utilizaciones.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee